FDA
-
-
-
-
-
-
-
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $29 at BofA Securities
-
-
-
-
-
-
-
ACADIA receives negative trend vote from EU regulators on Rett drug
-
-
-
-
-
-
-
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
-
-
-
-
-
-
-
ACADIA phase 3 trial for prader-willi syndrome treatment fails
-
-
-
-
-
-
-
ACADIA Pharmaceuticals names Konstantina Katcheves as chief business officer
-
-
-
-
-
-
-
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
-
325,460 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

